Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
100 results
  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Leukemia

24-172          Phase I

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

  • Pancreatic Cancer, Lung Cancer, Colorectal Cancer

25-022          Phase I

A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants with KRAS G12D Mutated Advanced Solid Tumors

  • Head and Neck Cancer, Melanoma

23-589          Phase I

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

  • Melanoma, Head and Neck Cancer, Lung Cancer, Bladder Cancer, Metastatic/Advanced Cancer

17-330          Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

  • Brain Tumors

22-532          Phase I

A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

  • Lymphoma

20-508          Phase I

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

  • Cellular Therapy

24-414          Phase II

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

  • Breast Cancer, Uterine Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Endometrial Cancer, Bladder Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Leukemia

21-751          Phase II

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Showing 31 - 40 of 100 results